2004
DOI: 10.1182/blood.v104.11.2932.2932
|View full text |Cite
|
Sign up to set email alerts
|

Observacional Study for Evaluation of Quality of Life in Patients with Chronic Myeloid Leukemia (CML) in Use of Gleevec® (Imatinib Mesilate).

Abstract: Purpose: Imatinib Mesilate is currently considered the most advanced therapy for CML due to its innovative molecular targeting mechanism of action, resulting in a high level of efficacy with a favorable toxicity profile which results in health-related quality of life (HRQL) benefits. We therefore decided to evaluate 230 patients with chronic myeloid leukemia (CML) treated with Imatinib Mesilate (Gleevec) as second line therapy, along 12 months, after failing Interferon (IFN) based therapy, due to lack of effic… Show more

Help me understand this report

This publication either has no citations yet, or we are still processing them

Set email alert for when this publication receives citations?

See others like this or search for similar articles